MRK vs VRTX: fair value comparison
Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, VRTX currently sits closer to the top of our discount ranking. VRTX carries the stronger quality grade.
| MRK | VRTX | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $143.93 | $515.44 |
| 12-month range | $82.49–$149.86 | $423.92–$547.65 |
| Sector rank | #95 of 113 Healthcare | #90 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: MRK fair value analysis · VRTX fair value analysis